Moderna (MRNA) Q1 earnings, revenue surprisingly tops consensus estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
PacWest, First Horizon, Paramount fall premarket; Shopify, Moderna rise
May 4, 2023 8:44 AM EDTInvesting.com -- Stocks in focus in premarket trade on Thursday, May 4th. Please refresh for updates.
PacWest Bancorp (NASDAQ: PACW) stock fell 40% after the regional lender confirmed it had been approached by "several potential partners... More
Dow futures fall 90 pts; banking turmoil continues after Fed hike
May 4, 2023 7:55 AM EDTInvesting.com -- U.S. stocks are seen opening in a subdued fashion Thursday as investors digest the Federal Reserves latest policy move as well as more turmoil in the banking sector.
At 06:55 ET (10:55 GMT), the Dow Futures contract was down 90 points or 0.3%, S&P 500 Futures traded 11 points or 0.3% lower, while Nasdaq 100 Futures climbed 10 points or 0.1%.
The main indices closed lower Wednesday after the U.S. central bank tightened monetary policy once more, lifting its benchmark interest rate by a further 25 basis points.
The blue-chip Dow Jones Industrial... More
Moderna reports surprise profit as it books deferred COVID vaccine sales
May 4, 2023 6:37 AM EDTBy Patrick Wingrove and Leroy Leo
(Reuters) - Moderna Inc on Thursday reported a small profit of 19 cents per share instead of an expected loss as it booked more revenue in the first quarter from last year's deferred orders for its COVID-19 vaccine than had been anticipated.Analysts expected a loss of $1.77 per share, according to Refinitiv data, and Moderna shares had jumped more than 5% to $136.71 by midday. They had fallen nearly 28% this year.
The company did not change its forecast of $5 billion in COVID vaccine sales for the year based on advance purchase agreements. But... More
Moderna (MRNA) Tops Q1 EPS by 194c
May 4, 2023 6:37 AM EDTModerna (NASDAQ: MRNA) reported Q1 EPS of $0.19, $1.94 better than the analyst estimate of ($1.75). Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.18 billion.
For earnings history and earnings-related data on Moderna (MRNA) click here.
... MoreModerna (MRNA) May weekly 130 straddle into results
May 4, 2023 5:32 AM EDTModerna (NASDAQ: MRNA) May weekly 130 straddle is priced for a move of 5.5% into the expected release of quarter results today before the bell.
... MoreModerna (MRNA) Announces Phase 1/2 Data on mRNA-3927
May 3, 2023 4:06 PM EDTAfter completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to determine a recommended dose
Moderna,Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that an abstract reporting on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA) has been accepted for presentation at the 2023 American Society of Gene + Cell Therapy (ASGCT)... More
